Table 1.
Baseline characteristics of eligible studies
| Reference | Year | Control | Country | Study design | Cancer types | IL-17A G-197A
|
IL-17F 7488T/C
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases
|
Controls
|
HWE | Cases
|
Controls
|
HWE | ||||||||||||||
| GG | GA | AA | GG | GA | AA | TT | TC | CC | TT | TC | CC | ||||||||
| Shibata17 | 2009 | HB | Japan | HB | Gastric cancer | 94 | 124 | 69 | 175 | 299 | 49 | Not | 221 | 55 | 4 | 419 | 100 | 4 | Yes |
| Wu20 | 2010 | PB | People’s Republic of China | PB | Gastric cancer | 210 | 485 | 250 | 193 | 371 | 204 | Yes | 540 | 332 | 55 | 527 | 214 | 36 | No |
| Wang11 | 2012 | PB | People’s Republic of China | PB | Breast cancer | 165 | 234 | 92 | 198 | 245 | 58 | Yes | 382 | 103 | 6 | 396 | 99 | 7 | Yes |
| Quan18 | 2012 | PB | People’s Republic of China | PB | Cervical cancer | 93 | 142 | 76 | 168 | 215 | 80 | Yes | 222 | 85 | 4 | 332 | 126 | 5 | Yes |
| Arisawa16 | 2012 | HB | Japan | HB | Gastric cancer | 112 | 137 | 84 | 218 | 293 | 72 | Yes | NA | NA | NA | NA | NA | NA | NA |
| Yuan10 | 2012 | HB | People’s Republic of China | HB | Ovarian cancer | 12 | 60 | 20 | 2 | 24 | 12 | Not | 10 | 69 | 13 | 2 | 34 | 2 | No |
| Zhang19 | 2014 | PB | People’s Republic of China | PB | Gastric cancer | 110 | 102 | 48 | 258 | 187 | 67 | Not | 209 | 30 | 21 | 429 | 53 | 30 | No |
| Zhou12 | 2013 | PB | People’s Republic of China | PB | Bladder cancer | 79 | 154 | 68 | 164 | 204 | 78 | Yes | 240 | 57 | 4 | 317 | 124 | 5 | Yes |
| Rafiei15 | 2013 | PB | Iran | PB | Gastric cancer | 56 | 61 | 44 | 78 | 72 | 21 | Yes | NA | NA | NA | NA | NA | NA | NA |
Notes: Yes means analyzed with the statistical software HWE. No means not analyzed with the statistical software HWE.
Abbreviations: HB, hospital-based studies; PB, population-based studies; IL, interleukin; HWE, Hardy–Winberg equilibrium; NA, no data.